Treating arterial stiffness in metabolic syndrome and type 2 diabetes mellitus

Open Hypertension Journal

Volumn 5, Issue SPEC.ISSUE, 2013, Pages 102-106

  Katsiki, Niki ^a   Gkaliagkousi, Eugenia ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antihypertensive; Antiplatelet drugs; Arterial stiffness; Hypoglycaemic; Hypolipidaemic drugs; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE SYNTHASE; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; CALCIUM ANTAGONIST; CARVEDILOL; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENKEPHALINASE INHIBITOR; EPLERENONE; FLUINDOSTATIN; GLIMEPIRIDE; HEMOGLOBIN A1C; LABETALOL; METFORMIN; NEBIVOLOL; OMEGA 3 FATTY ACID; PIOGLITAZONE; PITAVASTATIN; PLACEBO; SPIRONOLACTONE; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; CARDIOVASCULAR RISK; DIET; ELASTICITY; EXERCISE; HEART HEMODYNAMICS; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PULSE WAVE; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION;

EID: 84896823277     PISSN: None     EISSN: 18765262     Source Type: Journal    
DOI: 10.2174/1876526201305010102     Document Type: Article

References (90)

1. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2013 Apr 25. [Epub ahead of print]
2. Athyros VG, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin 2013; 29: 1263-74.
3. Doonan RJ, Hausvater A, Scallan C, Mikhailidis DP, Pilote L, Daskalopoulou SS. The effect of smoking on arterial stiffness. Hypertens Res 2010; 33: 398-410.
4. Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010; 8: 155-68.
5. Christen AI, Armentano RL, Miranda A, et al. Arterial wall structure and dynamics in type 2 diabetes mellitus methodological aspects and pathophysiological findings. Curr Diabetes Rev 2010; 6: 367-77.
6. Koumaras C, Tzimou M, Stavrinou E, et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs 2012; 12: 143-56.
7. Huck CJ, Bronas UG, Williamson EB, Draheim CC, Duprez DA, Dengel DR. Noninvasive measurements of arterial stiffness: repeatability and interrelationships with endothelial function and arterial morphology measures. Vasc Health Risk Manage 2007; 3: 343-9.
8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-357.
9. Cernes R, Zimlichman R, Shargorodsky M. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Adv Cardiol 2008; 45: 65-81.
10. Mansour AS, Yannoutsos A, Majahalme N, et al. Aortic stiffness and cardiovascular risk in type 2 diabetes. J Hypertens 2013; 31:1584-92.
11. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events. The Framingham Heart Study. Circulation 2010; 121: 505-11.
12. Wang KL, Cheng HM, Sung SH, et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension 2010; 55: 799-805.
13. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-27.
14. Seherstedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-91.
15. Seherstedt T, Jeppesen J, Hansen TW, et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham, and ESH/ESC risk charts. J Hypertens 2012; 30:1928-36.
16. Iguchi A, Yamakage H, Tochiya M, et al. Effects of Weight Reduction Therapy on Obstructive Sleep Apnea Syndrome and Arterial Stiffness in Patients with Obesity and Metabolic Syndrome. J Atheroscler Thromb 2013 Jul 25 [Epub ahead of print]
17. Nordstrand N, Gjevestad E, Hertel JK, et al. Arterial stiffness, lifestyle intervention and a low-calorie diet in morbidly obese patients-a nonrandomized clinical trial. Obesity (Silver Spring) 2013; 21: 690-7.
18. Figueroa A, Vicil F, Sanchez-Gonzalez MA, et al. Effects of diet and/or low-intensity resistance exercise training on arterial stiffness, adiposity, and lean mass in obese postmenopausal women. Am J Hypertens 2013; 26: 416-23.
19. Weisbrod RM, Shiang T, Al Sayah L, et al. F. Arterial Stiffening Precedes Systolic Hypertension in Diet-Induced Obesity. Hypertension 2013 Sep 23. [Epub ahead of print]
20. Wolfson N, Garish D, Goldberg Y, Boaz M, Matas Z, Shargorodsky M. Effect of weight loss maintenance on arterial compliance and metabolic and inflammatory parameters: a three-year follow-up study. Ann Nutr Metab 2010; 57: 204-10.
21. van de Laar RJ, Stehouwer CD, van Bussel BC, et al. Lower lifetime dietary fiber intake is associated with carotid artery stiffness: the Amsterdam Growth and Health Longitudinal Study. Am J Clin Nutr 2012; 96: 14-23.
22. Aatola H, Koivistoinen T, Hutri-Kähönen N, et al. Lifetime fruit and vegetable consumption and arterial pulse wave velocity in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation 2010; 122: 2521-8.
23. Livingstone KM, Lovegrove JA, Cockcroft JR, Elwood PC, Pickering JE, Givens DI. Does dairy food intake predict arterial stiffness and blood pressure in men?: Evidence from the Caerphilly Prospective Study. Hypertension 2013; 61: 42-7.
24. Crichton GE, Elias MF, Dore GA, Abhayaratna WP, Robbins MA. Relations between dairy food intake and arterial stiffness: pulse wave velocity and pulse pressure. Hypertension 2012; 59: 1044-51.
25. Hu J, Jiang X, Li N, et al. Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertens Res 2009; 32: 282-8.
26. Ruel G, Lapointe A, Pomerleau S, et al. Evidence that cranberry juice may improve augmentation index in overweight men. Nutr Res 2013; 33: 41-9.
27. Mucalo I, Jovanovski E, Rahelić D, Božikov V, Romić Z, Vuksan V. Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjects with type-2 diabetes and concomitant hypertension. J Ethnopharmacol 2013 Aug 22 [Epub ahead of print]
28. van de Laar RJ, Ferreira I, van Mechelen W, Prins MH, Twisk JW, Stehouwer CD. Lifetime vigorous but not light-to-moderate habitual physical activity impacts favorably on carotid stiffness in young adults: the Amsterdam growth and health longitudinal study. Hypertension 2010; 55: 33-9.
29. Jae SY, Heffernan KS, Fernhall B, et al. Association between cardiorespiratory fitness and arterial stiffness in men with the metabolic syndrome. Diabetes Res Clin Pract 2010; 90: 326-32.
30. Yokoyama H, Emoto M, Fujiwara S, et al. Short-term aerobic exercise improves arterial stiffness in type 2 diabetes. Diabetes Res Clin Pract 2004; 65: 85-93.
31. Roque FR, Hernanz R, Salaices M, Briones AM. Exercise training and cardiometabolic diseases: focus on the vascular system. Curr Hypertens Rep 2013; 15: 204-14.
32. Madden KM, Lockhart C, Cuff D, Potter TF, Meneilly GS. Aerobic training-induced improvements in arterial stiffness are not sustained in older adults with multiple cardiovascular risk factors. J Hum Hypertens 2013; 27: 335-9.
33. Dobrosielski DA, Gibbs BB, Ouyang P, et al. Effect of exercise on blood pressure in type 2 diabetes: a randomized controlled trial. J Gen Intern Med 2012; 27: 1453-9.
34. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. J Hepatol 2012; 57: 476.
35. Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease? Public Health 2013; 127: 435-41.
36. Athyros VG, Tziomalos K, Katsiki N, et al, For The Greace Study Collaborative Group. The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. Curr Vasc Pharmacol 2013; 11: 779-84.
37. Takami T, Saito Y. Effects of smoking cessation on central blood pressure and arterial stiffness. Vasc Health Risk Manag 2011; 7: 633-8.
38. Yu-Jie W, Hui-Liang L, Bing L, Lu Z, Zhi-Geng J. Impact of smoking and smoking cessation on arterial stiffness in healthy participants. Angiology 2013; 64: 273-80.
39. Mäki-Petäjä KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009; 15: 290-303.
40. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007; 11: 1143-60.
41. Mukherjee S, Mukhopadhyay P, Pandit K, Mukherjee S, Chowdhury S. Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. J Indian Med Assoc 2008; 106: 716-9.
42. Shinohara K, Shoji T, Kimoto E, et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005; 12: 205-10.
43. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17: 1513-7.
44. Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2009; 16: 539-45.
45. Hiukka A, Westerbacka J, Leinonen ES, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 20086; 52: 2190-7.
46. Shearer GC, Pottala JV, Hansen SN, Brandenburg V, Harris WS. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res 2012; 53: 2429-35.
47. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol 2010; 8: 638-44.
48. Losurdo P, Grillo A, Panizon E, et al. Supplementation of Omega-3 Polyunsaturated Fatty Acids Prevents Increase in Arterial Stiffness After Experimental Menopause. J Cardiovasc Pharmacol Ther 2013 Sep 13. [Epub ahead of print]
49. Pase MP, Grima NA, Sarris J. The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. Am J Clin Nutr 2011; 93: 446-54.
50. Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of reninangiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2013 Oct 16. doi:pii: S1933-1711(13)00167-8. 10.1016/j.jash.2013.09.001. [Epub ahead of print]
51. Ichihara A, Hayashi M, Koura Y, Tada Y, Hirota N, Saruta T. Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens 2003; 16: 959-65.
52. Mitchell GF, Lacourcière Y, Arnold JM, Dunlap ME, Conlin PR, Izzo JL Jr. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension 2005; 46: 1111-7.
53. Dudenbostel T, Glasser SP. Effects of antihypertensive drugs on arterial stiffness. Cardiol Rev 2012; 20: 259-63.
54. Adji A, O'Rourke MF, Namasivayam M. Arterial stiffness, its assessment, prognostic value, and implications for treatment. Am J Hypertens 2011; 24: 5-17.
55. Pedersen ME, Cockcroft JR. What is the role, if any, for betablockers as initial therapy for uncomplicated hypertension? Curr Opin Cardiol 2009; 24: 325-32.
56. Pende A, Dallegri F. Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control? Curr Pharm Des 2012; 18: 1011-20.
57. Agarwal R. Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2007; 16: 409-15.
58. Andreadis EA, Sfakianakis ME, Tsourous GI, et al. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness. Int Angiol 2010; 29: 266-72.
59. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manage 2009; 5: 353-60.
60. Raij L, Gonzalez-Ochoa AM. Vascular compliance in blood pressure. Curr Opin Nephrol Hypertens 2011; 20: 457-64.
61. Ong KT, Delerme S, Pannier B, et al; investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and longterm antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 2011; 29: 1034-42.
62. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a metaanalysis and meta-regression of randomised controlled trials. Atherosclerosis 2012; 221: 18-33.
63. Mallareddy M, Parikh CR, Peixoto AJ. Effect of angiotensinconverting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2006; 8: 398-403.
64. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54: 409-13.
65. Doumas M, Athyros V, Katsiki N, Reklou A, Lazaridis A, Karagiannis A. The effect of antihypertensive drugs on arterial stiffness and central hemodynamics: not all fingers are made the same. Open J Hypertens 2013 [in press].
66. Briet M, Schiffrin EL. Treatment of arterial remodeling in essential hypertension. Curr Hypertens Rep 2013; 15: 3-9.
67. Liang J, Zhou N, Teng F, et al. Hemoglobin A1c levels and aortic arterial stiffness: the Cardiometabolic Risk in Chinese (CRC) study. PLoS One 2012; 7: e38485.
68. Shen L, Zhang YG, Liu M, et al. Increased Arterial Stiffness in Subjects with Pre-diabetes among Middle Aged Population in Beijing, China. Biomed Environ Sci 2013; 26: 717-25.
69. Chen Y, Huang Y, Li X, et al. Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension. Endocrine 2009; 36: 262-7.
70. Nestel P. Relationship between arterial stiffness and glucose metabolism in women with metabolic syndrome. Clin Exp Pharmacol Physiol 2006; 33: 883-6.
71. Zieman SJ, Kamineni A, Ix JH, et al. Hemoglobin A1c and arterial and ventricular stiffness in older adults. PLoS One 2012; 7: e47941.
72. Choi SW, Shin MH, Yun WJ, et al. Association between hemoglobin A1c, carotid atherosclerosis, arterial stiffness, and peripheral arterial disease in Korean type 2 diabetic patients. J Diabetes Complicat 2011; 25: 7-13.
73. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during oneyear metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol 2012; 11: 61.
74. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010; 95: 722-30.
75. Kiyici S, Ersoy C, Kaderli A, et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 2009; 86: 44-50.
76. Ohira M, Endo K, Oyama T, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 2011; 60: 78-85.
77. Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2009; 58: 739-45.
78. Goldberg RB. Thiazolidinediones and vascular damage. Curr Opin Endocrinol Diabetes Obes 2007; 14: 108-15.
79. Araki T, Emoto M, Teramura M, et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism 2006; 55: 996-1001.
80. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract 2010; 64: 1796-801.
81. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14: 561-7.
82. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-6.
83. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012; 29: 1115-8.
84. Kim NH, Kim HY, An H, et al. Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial. Diabetol Metab Syndr 2013; 5: 41.
85. Athyros VG, Hatzitolios AI, Karagiannis A, et al. IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7: 984-92.
86. Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9: 647-57.
87. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83.
88. Zhao XH, Xu ZR, Zhang Q, Gu HF, Yang YM. Effect of intensive multifactorial treatment on the intima-media thickness of large arteries in patients with new-onset type 2 diabetes mellitus. J Zhejiang Univ Sci B 2012; 13: 378-85.
89. Janssen PG, Gorter KJ. Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009; 59: 43-8.
90. Johansen NB, Charles M, Vistisen D, et al. Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screendetected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2012; 35: 2207-14.